Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

Lacy, M Q; Hayman, S R; Gertz, M A; Short, K D; Dispenzieri, A; Kumar, S; Greipp, P R; Lust, J A; Russell, S J; Dingli, D; Zeldenrust, S; Fonseca, R; Bergsagel, P L; Roy, V; Mikhael, J R; Stewart, A K; Laumann, K; Allred, J B; Mandrekar, S J; Rajkumar, S V; Buadi, F

Lacy, M Q; Hayman, S R; Gertz, M A; Short, K D; Dispenzieri, A; Kumar, S; Greipp, P R; Lust, J A; Russell, S J; Dingli, D; Zeldenrust, S; Fonseca, R; Bergsagel, P L; Roy, V; Mikhael, J R; Stewart, A K; Laumann, K; Allred, J B; Mandrekar, S J; Rajkumar, S V; Buadi, F.

Affiliation

Lacy MQ; Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. lacy.martha@mayo.edu

Leukemia ; 24(11): 1934-9, 2010 Nov.

Article in En | MEDLINE | ID: mdl-20827286

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Multiple Myeloma Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google